Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of Bcps's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bcps with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bcps more than expected).
This network shows the impact of papers produced by Bcps. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bcps. The network helps show where Bcps may publish in the future.
Co-authorship network of co-authors of Bcps
This figure shows the co-authorship network connecting the top 25 collaborators of Bcps.
A scholar is included among the top collaborators of Bcps based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Bcps. Bcps is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Bubalo, Joseph, et al.. (2019). Ibrutinib-Related Atrial Fibrillation: An Anticoagulant Challenge.
2.
Witt, Daniel M., et al.. (2017). Emotional Impact of Venous Thromboembolism: A Qualitative Study of Patients’ Journeys.3 indexed citations
3.
Bcps, et al.. (2016). Adjusted Dosing and Schedule of Pemetrexed in Impaired Renal Function.1 indexed citations
4.
Roffman, David S., et al.. (2016). Cardiovascular Pharmacology, 3rd Edition.
5.
Stewart, David W., PharmD, & Bcps. (2015). Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer. Journal of Oncology Practice. 4(4). 110–114.1 indexed citations
6.
PharmD, et al.. (2015). Adult ADHD: A Review of the Clinical Presentation, Challenges, and Treatment Options. The Psychiatric times. 32(10). 41–41.2 indexed citations
7.
PharmD, et al.. (2015). Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost.3 indexed citations
8.
Ptachcinski, Richard J., et al.. (2014). Reducing Hospital Readmissions: A New Opportunity for Community Pharmacists.1 indexed citations
9.
PharmD, et al.. (2013). Medication Errors in Adults—Case #3: Duplicate Therapy.1 indexed citations
10.
PharmD, et al.. (2013). Medication Errors in Adults—Case #4: Chemotherapy Drug Interactions.
11.
PharmD, et al.. (2013). Medication Errors in Adults—Case #1: Warfarin.1 indexed citations
12.
Sobieraj, Diana M, PharmD, & Bcps. (2013). FDA approves first SGLT2 inhibitor for T2DM.2 indexed citations
13.
Sobieraj, Diana M, PharmD, Bcps, & Craig I Coleman. (2012). Apixaban: An orally active factor Xa inhibitor to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation.1 indexed citations
14.
O’Dell, Kate M., PharmD, & Bcps. (2012). Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis.4 indexed citations
15.
O’Dell, Kate M., PharmD, & Bcps. (2012). Linaclotide: A guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.2 indexed citations
16.
PharmD, et al.. (2010). Guideline-specific management of atrial fibrillation.
17.
Sobieraj, Diana M, PharmD, & Bcps. (2010). Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis. 45(8). 245–251.1 indexed citations
18.
Mandos, Laura A., et al.. (2009). Achieving Remission in Generalized Anxiety Disorder.2 indexed citations
19.
Kirwin, Jennifer L., PharmD, & Bcps. (2007). Pramipexole: A nonergot-derived dopamine agonist for the treatment of restless legs syndrome. 42(3). 165–174.1 indexed citations
20.
DiVall, Margarita V., et al.. (2003). Palonosetron: A novel 5-HT3 receptor antagonist for chemotherapy-associated nausea and vomiting.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.